/HMGN

HMGN Stock - Hemagen Diagnostics, Inc.

Q: What is the analyst price target for HMGN?

Analyst price target information is not currently available for HMGN.

Q: What is HMGN's market cap?

Market capitalization information is not currently available for HMGN.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for HMGN

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2008

FY2009

FY2010

FY2011

FY2012

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.36

52W High$0.01

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2012	FY2011	FY2010	FY2009	FY2008
Revenue	$4.04M	$5.14M	$5.22M	$5.42M	$6.37M
Gross Profit	$1.61M	$1.96M	$2.36M	$2.07M	$2.77M
Gross Margin	39.9%	38.1%	45.1%	38.2%	43.5%
Operating Income	$-437,914	$-472,717	$235,946	$-348,714	$118,034
Net Income	$-907,315	$-880,476	$-156,314	$-808,148	$427,163
Net Margin	-22.4%	-17.1%	-3.0%	-14.9%	6.7%
EPS	$-0.06	$-0.06	$-0.01	$-0.05	$0.03

Company Overview

Hemagen Diagnostics, Inc., a biotechnology company, provides human and veterinary clinical diagnostic solutions worldwide. The company develops, manufactures, and markets VIRGO, a human clinical diagnostic line of immunoassays for the diagnosis of autoimmune and infectious diseases, and acute phase proteins. Its human diagnostics products also comprise Universal IFA components; supplies, controls and calibrators, accessories, and H-rotors; reagents, electrodes, equipment; and specialty assays, including Chagas, acute phase proteins, and cytokines. In addition, the company provides veterinary diagnostic products, such as equipment, reagents, supplies, accessories, and electrodes in chemistry, hematology, and electrolyte areas. It sells its products directly, as well as through distributors to various laboratories, hospitals, and blood banks. The company was founded in 1985 and is based in Columbia, Maryland.

Visit Website

Frequently Asked Questions about HMGN

What is HMGN's current stock price?

Hemagen Diagnostics, Inc. (HMGN) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for HMGN?

No analyst price targets are currently available for this stock.

What sector is Hemagen Diagnostics, Inc. in?

Hemagen Diagnostics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the OTC exchange.

What is HMGN's market cap?

Hemagen Diagnostics, Inc. has a market capitalization of $0.00 billion, making it a small-cap company.

Does HMGN pay dividends?

No, Hemagen Diagnostics, Inc. does not currently pay a dividend to shareholders.